Phase 2/3 clinical trial data readouts for pipeline programs (thalassemia, sickle cell indications for mitapivat)
FDA regulatory decisions and label expansion approvals for PYRUKYND
Quarterly PYRUKYND prescription trends and revenue growth trajectory
Cash runway updates and financing announcements (equity raises, partnerships, asset sales)
low - Rare disease treatments are non-discretionary medical necessities with demand largely insulated from GDP fluctuations. Patient populations are small and clinically defined, not economically sensitive. However, severe recessions could pressure payer reimbursement rates or delay elective diagnostic testing that identifies patients.
Rising rates negatively impact valuation multiples for pre-profitable biotech (higher discount rates on distant cash flows) and increase opportunity cost versus fixed income. Financing costs rise if Agios needs to raise capital, though current minimal debt (0.03 D/E) limits direct interest expense impact. Rate increases typically compress biotech valuations 15-30% as risk-free alternatives become more attractive.
Binary clinical trial risk - single failed Phase 3 study can eliminate 50-80% of market value overnight in small-cap biotech
Regulatory pathway uncertainty for rare disease indications with limited precedent and evolving FDA standards for accelerated approval
Reimbursement pressure from payers increasingly scrutinizing ultra-high-cost orphan drugs despite unmet need
growth - Speculative biotech investors seeking asymmetric returns from clinical catalysts and regulatory approvals. Attracts event-driven hedge funds around data readouts and venture-style investors willing to accept binary risk. Not suitable for value or income investors given negative earnings, no dividend, and high volatility. Recent -40% 3-month decline reflects risk-off rotation out of pre-revenue biotech.
Trend
-5.6% vs SMA 50 · -15.1% vs SMA 200
Momentum
Distribution pattern detected. More selling days than accumulation over the past 20 sessions. Not a conducive environment for a squeeze.
Based on volume distribution analysis. Direct short interest data (short float %, days to cover) is not available in current data sources.
ANALYST ESTIMATES
Analyst consensus estimates · Actuals replace estimates as reported
| Year | Revenue Est. | Rev Gth | EPS Est. | EPS Gth | Range | Analysts |
|---|---|---|---|---|---|---|
FY2025 | $46.1M $45.1M–$47.5M | — | -$7.06 | — | ±2% | High8 |
FY2026(current) | $120.2M $100.7M–$150.6M | ▲ +160.6% | -$6.13 | — | ±16% | High8 |
FY2027 | $260.0M $174.6M–$352.7M | ▲ +116.3% | -$4.68 | — | ±27% | High9 |
INSTITUTIONAL OWNERSHIP
AGIO News
About
at agios, we are doing incredibly important and difficult work. we are trying to discover and develop breakthrough medicines, and we have a clear motivator — people with cancer and rare genetic diseases who are counting on us to be successful. we are a science-driven research organization. we have built a discovery platform upon our expertise in the fields of cellular metabolism and precision medicine across three major focus areas: cancer metabolism, rare genetic metabolic disorders and metabolic immuno-oncology. it takes people with a diversity of thought, skills, passions and backgrounds to get us from the first stages of understanding new biology and discovering drugs to our ultimate goal of getting these medicines to patients who are waiting for them. our connection to one another and our work and our commitment to our values enable us to potentially change the practice of medicine by by striving for excellence and doing things differently. we call this the "other side of possible
| Symbol | Price | Day % | Mkt Cap↓ | P/E | Rev Grw | Margin | ELO |
|---|---|---|---|---|---|---|---|
AGIO◀ | $28.17 | +0.00% | $1.7B | — | — | — | 1500 |
| $66.13 | -5.07% | $13.0B | — | +12626.1% | -14525.8% | 1500 | |
| $94.92 | -3.79% | $12.6B | — | +3288.2% | -4239.0% | 1500 | |
| $523.69 | -3.00% | $12.1B | — | +43205.3% | -3008.0% | 1500 | |
| $227.72 | -1.30% | $11.7B | — | +6554.5% | -2868.8% | 1500 | |
| $57.90 | -0.86% | $11.2B | 50.3 | +1459.3% | 147.7% | 1500 | |
| $76.67 | -3.79% | $10.8B | — | +2325815.3% | -19.7% | 1500 | |
| Sector avg | — | -2.54% | — | 50.3 | +398824.8% | -4085.6% | 1500 |